Rockwell Medical will Present Data on Triferic Intravenous (IV) Administration at the 19th International Conference on Dialy...
January 26 2017 - 8:30AM
Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated
biopharmaceutical company targeting end-stage renal disease (ESRD)
and chronic kidney disease (CKD) with innovative products for the
treatment of iron replacement, secondary hyperparathyroidism and
hemodialysis, announced today that it will present data on the
Pharmacokinetics of Triferic Administered IV and via HD at the
Renal Research Institute 19th International Conference on Dialysis
February 1-3, 2017 at Caesar’s Palace in Las Vegas. Triferic is the
only FDA approved therapy indicated to replace iron replacement and
maintain hemoglobin in chronic kidney disease patients receiving
dialysis.
Presentation Details:
Session Title: Pharmacokinetics of
Triferic Administered IV and via HDSession Date and Time: Thursday
February 2, 2017: 7:00-8:00am Pacific TimePoster #: 018
Raymond D. Pratt, MD, FACP, Chief Medical
Officer for Rockwell Medical stated, “These new data demonstrate
that Triferic can be administered intravenously and deliver the
same amount of iron that is delivered when Triferic is administered
via dialysate, without increasing iron stores. This amount is
sufficient to maintain hemoglobin concentrations in hemodialysis
patient.”
About TrifericTriferic is the
only FDA approved drug indicated to replace iron and maintain
hemoglobin in hemodialysis patients suffering from anemia. Via
dialysate during each dialysis treatment, Triferic replaces the 5-7
mg iron loss that occurs in all patients, effectively maintaining
their iron balance. Unlike IV iron products, Triferic binds iron
immediately and completely to transferrin (carrier of iron in the
body) upon entering the blood and it is then transported directly
to the bone marrow to be incorporated into hemoglobin, with no
increase in ferritin (stored iron and inflammation) and no
anaphylaxis, addressing a significant unmet need in overcoming
Functional Iron Deficiency (FID) in ESRD patients. Please visit
www.triferic.com to view the Triferic mode-of-action (MOA) video
and for more information.
About Renal Research
InstituteRenal Research Institute is dedicated to
advancing therapy options for dialysis patients to provide the
highest caliber of care based on advanced clinical technology.
Renal Research Institute operates as a subsidiary of Fresenius
Medical Care. The 19th International Conference on Dialysis
Advances in Kidney Disease is a forum for up-to-date presentations
on new technology and therapeutics in the field of kidney disease,
emphasizing current issues facing the renal community. The
conference, which is jointly sponsored by the University of
Minnesota, will take place February 1-3, 2017 at Caesar’s Palace in
Las Vegas, Nevada. For more information refer to
http://renalresearch.com/.
About Rockwell MedicalRockwell
Medical is a fully-integrated biopharmaceutical company targeting
end-stage renal disease (ESRD) and chronic kidney disease (CKD)
with innovative products for the treatment of iron replacement,
secondary hyperparathyroidism and hemodialysis.
Rockwell’s anemia drug Triferic is the only
FDA approved product indicated for iron replacement and maintenance
of hemoglobin in hemodialysis patients. Triferic delivers iron to
patients during their regular dialysis treatment, using dialysate
as the delivery mechanism. Triferic has demonstrated that it safely
and effectively delivers sufficient iron to the bone marrow and
maintains hemoglobin, without increasing iron stores (ferritin).
Rockwell intends to market Triferic to hemodialysis patients in the
U.S. dialysis market and globally.
Rockwell’s FDA approved generic drug Calcitriol
is for treating secondary hyperparathyroidism in dialysis patients.
Calcitriol (active vitamin D) injection is indicated in the
management of hypocalcemia in patients undergoing chronic renal
dialysis. It has been shown to significantly reduce elevated
parathyroid hormone levels. Reduction of PTH has been shown to
result in an improvement in renal osteodystrophy. Rockwell
intends to market Calcitriol to hemodialysis patients in the U.S.
dialysis market.
Rockwell is also an established manufacturer and
leader in delivering high-quality hemodialysis
concentrates/dialysates to dialysis providers and distributors in
the U.S. and abroad. As one of the two major suppliers in the U.S.,
Rockwell’s products are used to maintain human life by removing
toxins and replacing critical nutrients in the dialysis patient’s
bloodstream. Rockwell has three U.S. manufacturing/distribution
facilities.
Rockwell’s exclusive renal drug therapies
support disease management initiatives to improve the quality of
life and care of dialysis patients and are intended to deliver safe
and effective therapy, while decreasing drug administration costs
and improving patient convenience. Rockwell Medical is developing a
pipeline of drug therapies, including extensions of Triferic for
indications outside of hemodialysis. Please visit
www.rockwellmed.com for more information.
Certain statements in this press release
constitute "forward-looking statements" within the meaning of the
federal securities laws, including, but not limited to, Rockwell’s
intention to sell and market Calcitriol and Triferic. Words such as
“may,” “might,” “will,” “should,” “believe,” “expect,”
“anticipate,” “estimate,” “continue,” “predict,” “forecast,”
“project,” “plan”, “intend” or similar expressions, or statements
regarding intent, belief, or current expectations, are
forward-looking statements. While Rockwell Medical believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to us on the date of this release.
These forward looking statements are based upon current estimates
and assumptions and are subject to various risks and uncertainties,
including without limitation those set forth in Rockwell Medical’s
SEC filings. Thus, actual results could be materially different.
Rockwell Medical expressly disclaims any obligation to update or
alter statements whether as a result of new information, future
events or otherwise, except as required by law.
Triferic® is a registered trademark of Rockwell
Medical, Inc.
Michael Rice, Investor Relations; 646-597-6979
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Apr 2023 to Apr 2024